Gritstone bio Executive Compensation (FY23)
GRTS · Executive and director compensation, fiscal 2022 to 2023
Chief executive, fiscal 2023 ◇ Andrew Allen |
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
The Gritstone bio brief, $500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $900.
Data as of November 6, 2026Latest filing (DEF 14A): April 29, 2024
1 filing cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Intel, one year, every company
81 figures on this page, cited to the filing that reported them. See the citations
Frequently asked questions
Answers drawn from the data on this page.
Who is Gritstone bio's chief executive and what were they paid?
Andrew Allen, President and Chief Executive Officer, received $3,444,071 in total compensation for fiscal 2023.
Which companies are in Gritstone bio's peer group?
Companies named in the disclosed peer group include AlloVir, Arbutus Biopharma Corporation, Arcturus Therapeutics Inc., Atara Biotherapeutics Inc. and Celularity Inc., among others.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Andrew Allen President and Chief Executive Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | — not reconciled |
Karin Jooss Executive Vice President and Head of Research & Development | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Erin Jones Executive Vice President and Chief Operating Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Andrew Allen President and Chief Executive Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Karin Jooss Executive Vice President and Head of Research & Development | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Erin Jones Executive Vice President and Chief Operating Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2023 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Andrew Allen | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | — | January 30, 2032 | |
| Option | ◇ | — | — | March 7, 2031 | |
| Option | ◇ | — | — | February 24, 2030 | |
| Erin Jones | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | — | January 30, 2032 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | — | March 7, 2031 | |
| Option | ◇ | — | — | February 24, 2030 | |
| Karin Jooss | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | — | January 30, 2032 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | — | March 7, 2031 | |
| Option | ◇ | — | — | February 24, 2030 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2023
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Elaine Jones, Ph.D Board chair | ◇ | — | ◇ | — | — | — | ◇ |
Steve Krognes | ◇ | — | ◇ | — | — | — | ◇ |
Naiyer Rizvi, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Shefali Agarwal, M.D., M.P.H | ◇ | — | ◇ | — | — | — | ◇ |
Clare Fisher | ◇ | — | ◇ | — | — | — | ◇ |
Lawrence Corey, M.D | ◇ | — | ◇ | — | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2023
- AlloVir symbol not shown
- Arbutus Biopharma Corporation ABUS
- Arcturus Therapeutics Inc. ARCT
- Atara Biotherapeutics Inc. ATRA
- Celularity Inc. CELU
- CytomX Therapeutics, Inc. CTMX
- Evelo Biosciences, Inc. EVLO
- Finch Therapeutics Group, Inc. symbol not shown
- IGM Biosciences, Inc. IGM
- Immunovant Inc. IMVT
- Jounce Therapeutics, Inc. MRSN
- Kura Oncology Inc. KURA
- Poseida Therapeutics, Inc. PSTX
- Precision BioSciences, Inc. DTIL
- Replimune Group, Inc. REPL
- Sutro Biopharma, Inc. STRO
- TCR2 Therapeutics symbol not shown
- Vaxart Inc. VXRT
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Andrew Allen (President and Chief Executive Officer), FY2023 total compensation $3,444,071 (base salary $645,833) [exec_comp, SEC accession 0001140361-24-023057, filed 2024-04-29]What this page does not include
Everything above is a fact Gritstone bio disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Gritstone bio sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
81 figures on this page, cited to the filing that reported them.
81 cited to the filing
Documents cited
- 0001140361-24-023057DIRECTOR COMPENSATION · Outstanding Equity Awards at 2023 Fiscal Year End · Summary Compensation Table
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Gritstone bio executive compensation, FY2022–FY2023.” https://intel.velarion.ai/comp/GRTS (accessed 2026).
Short form: data: Velarion
The Gritstone bio brief, $500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $900.
1 filing cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Gritstone bio and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Gritstone bio discloses
The companies named in GRTS's own disclosed peer group.
Arbutus Biopharma CorporationArcturus Therapeutics Inc.Atara Biotherapeutics Inc.Celularity Inc.CytomX Therapeutics, Inc.Evelo Biosciences, Inc.IGM Biosciences, Inc.Immunovant Inc.Jounce Therapeutics, Inc.Kura Oncology Inc.Poseida Therapeutics, Inc.Precision BioSciences, Inc.Replimune Group, Inc.Sutro Biopharma, Inc.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}